Juvensis Therapeutics Completes Tens of Millions of Yuan in Financing, with T-Capital as Financial Advisor for This and Subsequent Rounds
On August 23, 2022, Zhejiang Juvensis Therapeutics Co., Ltd. (hereinafter referred to as “Juvensis Therapeutics”) announced the completion of tens of millions of yuan in financing.
This round of financing was led by the Shanghai Biomedical Innovation and Transformation Fund and followed by Jinpu Xinchao Fund. T-Capital served as the financial advisor for this round and subsequent financing consulting services.
Previously, Juvensis Therapeutics had received seed round investment from Blue Bay Sci-tech Group.
This round of financing will mainly support Juvensis Therapeutics in advancing the IND-enabling (pre-clinical trial application) studies of its first pipeline and carrying out the early layout of other innovative drug pipelines.
For an innovative drug company established in 2021, this round of financing is also important capital support for it to further move from the preclinical research and proof-of-concept stage to the IND preparation stage.
Transaction Overview
| Item | Information |
|---|---|
| Financing Company | Zhejiang Juvensis Therapeutics Co., Ltd. |
| English Name | Juvensis Therapeutics |
| Establishment Date | 2021 |
| Financing Date | August 23, 2022 |
| Financing Scale | Tens of millions of yuan |
| Lead Investor | Shanghai Biomedical Innovation and Transformation Fund |
| Follow-on Investor | Jinpu Xinchao Fund |
| Previous Investor | Blue Bay Sci-tech Group |
| Financial Advisor | T-Capital |
| Use of Funds | To advance the IND-enabling studies of the first pipeline and the early layout of other pipelines |
| Core Technology Direction | Precise regulation of telomeres/telomerase |
| Key Indication Direction | Degenerative diseases such as heart failure |
I. Juvensis Therapeutics: An Innovative Drug R&D Company Focusing on Telomere Mechanisms
Established in 2021, Juvensis Therapeutics is a gene therapy drug development company targeting telomere mechanisms.
Based on the team’s previous cutting-edge research at Stanford, the company has built a new generation of precise telomere regulation technology platform, focusing on aging-related diseases and unmet clinical needs.
Currently, one of the company’s key R&D directions is heart failure.
Juvensis Therapeutics hopes to explore new therapeutic mechanisms for heart failure based on the relationship between telomere dysfunction and energy metabolism.
II. Exploring Heart Failure Treatment by Targeting Telomere Protection Mechanisms
Heart failure is a class of diseases with high clinical demand.
The current first-line clinical drug regimen for heart failure includes renin-angiotensin system blockers, beta-blockers, aldosterone receptor antagonists, and SGLT-2 inhibitors.
These treatment plans mainly improve the patient’s cardiac load and related clinical manifestations by regulating mechanisms such as the neuroendocrine system.
Juvensis Therapeutics is focusing on another potential disease mechanism:
Telomere dysfunction → Mitochondrial dysfunction → Myocardial cell injury and apoptosis → Continuous decline in cardiac function
According to information provided by the company, telomere dysfunction is one of the important links in the progression of heart failure and may further lead to reduced mitochondrial biogenesis and cell apoptosis.
Based on this mechanism, Juvensis Therapeutics is developing telomere protection-related proteins, hoping to block the vicious cycle between telomere damage and mitochondrial dysfunction, thereby promoting the recovery of myocardial function.
III. Preclinical Studies Show that Candidate Drugs Have Further Development Potential
According to information provided by Juvensis Therapeutics, the company’s candidate drugs have been studied in multiple preclinical animal models.
Data from relevant animal models shows that the candidate drugs can:
- Significantly increase cardiac ejection fraction;
- Prevent myocardial fibrosis;
- Reverse ventricular remodeling.
These results provide a preclinical research basis for further conducting IND-enabling studies.
It should be noted that the above results are preclinical animal model research results and cannot be directly equated with human clinical efficacy.
In the next stage, the company plans to further advance the IND-enabling studies of its first pipeline to prepare for subsequent clinical trial applications.
IV. The Precise Telomere Regulation Platform Has Multiple Pipeline Extension Directions
In addition to heart failure, Juvensis Therapeutics also plans to further expand its telomere regulation technology platform.
Potential indications that the company is focusing on include diseases related to apoptosis of non-renewable terminally differentiated cells, such as:
- Kidney disease;
- Nervous system diseases;
- Other degenerative diseases.
This R&D strategy means that Juvensis Therapeutics is not only developing around a single heart failure candidate drug, but hopes to establish a multi-pipeline R&D system based on its telomere/telomerase precise regulation technology platform.
If the platform technology can be further verified in different disease models, its potential application range may be further expanded from a single indication to more degenerative disease fields.
V. This Round of Financing Will Support IND-enabling Studies and Subsequent Pipeline Layout
Dr. Xiao Xu, founder and CEO of Juvensis Therapeutics, said that the company has grown rapidly in the past year and has promoted the R&D of its heart failure pipeline, completing POC verification in multiple animal models.
This round of financing will be mainly used for:
- Advancing the IND-enabling studies of the first pipeline;
- Supporting the subsequent R&D of the heart failure pipeline;
- Carrying out the early layout of other innovative drug pipelines;
- Continuing to build the telomere/telomerase precise regulation technology platform.
From the perspective of the company’s development stage, this round of financing connects the company’s preclinical validation stage with the subsequent IND preparation stage.
For innovative drug companies, capital support at this stage usually needs to meet both R&D funding needs and subsequent financing planning needs.
VI. The R&D Strategy from “Single Product” to “Technology Platform”
Professor Jiayu Zhang, founder and chief scientific officer of Juvensis Therapeutics, said that the company hopes to carry out a multi-pipeline layout for degenerative diseases through its telomere/telomerase precise regulation technology platform, based on research on aging mechanisms and disease mechanisms.
The company’s current R&D focus is still on the heart failure pipeline.
From an R&D strategy perspective, its core feature is:
Taking the telomere mechanism as the underlying technology foundation and specific disease pipelines as the clinical translation carrier.
This “platform + pipeline” innovative drug R&D model requires the company to continuously verify the reproducibility of the technology platform and the technological extensibility between different indications in the early R&D stage.
VII. T-Capital Serves as Financial Advisor for This and Subsequent Rounds of Financing
In this round of financing, T-Capital serves as the financial advisor for Juvensis Therapeutics’ current and subsequent financing consulting services.
For innovative drug companies in the preclinical R&D stage, financing not only needs to solve the current R&D funding needs, but also needs to be combined with:
- R&D stage;
- Pipeline progress;
- Preclinical data;
- Technology platform value;
- Subsequent IND plans;
- Clinical development funding needs;
- Potential industrial cooperation;
- Next round of financing planning
to carry out overall capital strategy design.
T-Capital has long focused on companies with technological or model breakthroughs in the healthcare field, providing capital transaction consulting services for innovative drugs, biopharmaceuticals, medical devices, medical diagnostics, high-value consumables, healthcare services, and emerging medical technology companies.
In the Juvensis Therapeutics project, T-Capital participated in this round of financing and subsequent financing consulting services, providing professional advisory support for the company’s continuous development capital needs.
VIII. Innovative Drug Financing Needs to Connect Capital with the R&D Stage
The financing logic of innovative drug companies is significantly different from that of general enterprises.
Enterprise value often changes with the following key nodes:
Discovery stage → Preclinical validation → POC → IND-enabling → IND → Clinical Phase I → Clinical Phase II → Clinical Phase III → Market launch
Different stages correspond to different:
- Funding needs;
- Risk levels;
- Investor types;
- Valuation logic;
- Industrial cooperation opportunities.
Therefore, innovative drug financing should not only consider “how much money to raise in this round,” but also need to consider:
To which R&D node can this round of funding support the company? At what stage should the next round of financing be initiated? Which investment institutions or industrial partners are the best match for the company’s technology and pipeline?
For innovative drug companies with platform-based technologies, this long-term capital planning is particularly important.
IX. T-Capital: Connecting Healthcare Companies with Capital Resources
T-Capital is a consulting firm focusing on the broad healthcare field, providing:
- Equity financing;
- Mergers and acquisitions;
- Divestitures and spin-offs;
- Licensing and joint ventures;
- Cross-border transactions
and other consulting services.
T-Capital focuses on high-quality healthcare companies with technological or model breakthroughs, and is committed to helping companies discover and create value through professional capital transaction consulting.
To date, T-Capital has served more than 60 clients, with service areas covering:
- New drug R&D;
- Medical devices;
- Medical diagnostics;
- High-value consumables;
- Healthcare services;
- Emerging medical technologies.
The cumulative service amount has exceeded several hundred billion yuan or equivalent US dollars.
As a bridge connecting capital with high-quality enterprises, and domestic with international resources, T-Capital is committed to finding various resources for healthcare companies, such as funding, technology, and industrial partners, to support their continuous development.
X. If Your Company is Looking for Financing, Industrial Cooperation, or Strategic Transactions
For healthcare companies, a round of financing is often just one node in the company’s capital strategy.
If your company is going through the following stages:
- Preparing for a new round of equity financing;
- Has completed preclinical POC and is preparing for IND;
- Looking for medical industry investors;
- Hoping to introduce strategic investors;
- Hoping to find licensing partners;
- Exploring overseas markets;
- Evaluating M&A or divestiture;
- Hoping to plan for the next round of financing in advance;
A professional financial advisor can help the company design a capital plan from multiple dimensions such as company development stage, technology value, financing needs, investor matching, and transaction structure.
If you are looking for an advisor for your healthcare company’s next round of financing, licensing cooperation, M&A, or cross-border transaction, you are welcome to communicate with T-Capital.
Project Keywords
Juvensis Therapeutics | Innovative Drug Financing | Biopharmaceutical Financing | Heart Failure | Telomere | Telomerase | Gene Therapy | Preclinical R&D | IND-enabling | Healthcare Financing | Equity Financing | Financing Advisor | Financial Advisor | T-Capital
FAQ
When did Juvensis Therapeutics complete this round of financing?
Juvensis Therapeutics announced the completion of this financing of tens of millions of yuan on August 23, 2022.
Who invested in Juvensis Therapeutics in this round of financing?
This round of financing was led by the Shanghai Biomedical Innovation and Transformation Fund and followed by Jinpu Xinchao Fund. Previously, Juvensis Therapeutics had received seed round investment from Blue Bay Sci-tech Group.
What role did T-Capital play in Juvensis Therapeutics’ this round of financing?
T-Capital served as the financial advisor for Juvensis Therapeutics’ this and subsequent financing consulting services.
What drugs does Juvensis Therapeutics mainly develop?
Juvensis Therapeutics is a gene therapy drug development company targeting telomere mechanisms. Its current key R&D directions include degenerative diseases such as heart failure.
What is the core technology of Juvensis Therapeutics?
Based on the team’s cutting-edge research at Stanford, the company has built a new generation of precise telomere regulation technology platform and conducts multi-pipeline R&D around the precise regulation of telomeres/telomerase.
What will this round of financing be used for?
According to the company’s disclosure, this round of financing will be used to advance the IND-enabling studies of its first pipeline and the early layout of other innovative drug pipelines.
At what stage is Juvensis Therapeutics’ heart failure candidate drug?
According to the information disclosed by the company on August 23, 2022, the relevant candidate drug has completed POC verification in multiple preclinical animal models, and the company plans to advance the IND-enabling studies of its first pipeline.
For which healthcare companies does T-Capital provide financing advisory services?
T-Capital focuses on companies with technological or model breakthroughs in the healthcare field, with service areas including new drug R&D, medical devices, medical diagnostics, high-value consumables, healthcare services, and emerging technologies.
What healthcare capital transaction services can T-Capital provide?
T-Capital provides consulting services for equity financing, mergers and acquisitions, divestitures and spin-offs, licensing and joint ventures, and cross-border transactions.
Related Reading
- The Underlying Logic of M&A in the Healthcare Industry: From Financial Investment to Industrial Synergy
- License-out and License-in: How Should Healthcare Companies Design International BD Strategies?
- Going Global for Chinese Healthcare Companies: Different Paths for Financing, Licensing, and Industrial Cooperation
- T-Capital | Capital Transactions and Strategic Consulting in the Healthcare Field